Journal
FRONTIERS IN NEUROENDOCRINOLOGY
Volume 35, Issue 3, Pages 370-384Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.yfrne.2014.02.002
Keywords
Sex differences; Parkinson's disease; Nigrostriatal dopaminergic pathways; Sex hormones; Neuroprotection
Categories
Funding
- Wellcome Trust [086871/Z/08/Z]
- Imperial College London Junior Research Fellowship
- Wellcome Trust [086871/Z/08/Z] Funding Source: Wellcome Trust
Ask authors/readers for more resources
Parkinson's disease (PD) displays a greater prevalence and earlier age at onset in men. This review addresses the concept that sex differences in PD are determined, largely, by biological sex differences in the NSDA system which, in turn, arise from hormonal, genetic and environmental influences. Current therapies for PD rely on dopamine replacement strategies to treat symptoms, and there is an urgent, unmet need for disease modifying agents. As a significant degree of neuroprotection against the early stages of clinical or experimental PD is seen, respectively, in human and rodent females compared with males, a better understanding of brain sex dimorphisms in the intact and injured NSDA system will shed light on mechanisms which have the potential to delay, or even halt, the progression of PD. Available evidence suggests that sex-specific, hormone-based therapeutic agents hold particular promise for developing treatments with optimal efficacy in men and women. (C) 2014 The Authors. Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available